CPI, the Cell and Gene Therapy Catapult and MicrofluidX announce development of technology to rapidly scale up cell and gene therapy manufacture -…

Posted on by

London UK, 27th July 2020 CPI, MicrofluidX and the Cell and Gene Therapy Catapult (CGT Catapult) announced today their collaboration in a project to develop bioprocessing technology for the rapid scale-up of cell and gene therapies.

The technology has the potential to overcome a major bottleneck in the development of these novel treatments, and reduce the time and costs associated with bringing such therapies to market.

Significant advances have been made in recent years in the use of cell and gene therapies in disease areas with unmet clinical needs. However, reliable methods are still required to scale up the manufacture of these complex technologies to commercial levels. Cell and gene therapies are produced from inherently variable living cells. As such, it is highly challenging to achieve consistent performance at different scales, which can lead to prolonged development times. In turn, this can significantly raise the cost of these therapies upon entry to the market.

The microfluidic cell culture technology being developed by MicrofluidX will provide manufacturers of cell and gene therapies with fine process control throughout development, ensuring consistent quality. The technology can be used to optimise cell characteristics and growth conditions early in development, before rapidly transitioning to large-scale manufacturing without the need to invest time in redesigning processes. Crucially, using microfluidics greatly reduces the consumption of expensive reagents, cutting down overall development costs. MicrofluidX recently closed an initial funding round raising 1.4 million for its microfluidic platform. The company is now working with CPI and CGT Catapult to secure further funding and validate its prototypes.

CPI is an independent technology innovation centre and founding member of the UK Governments High Value Manufacturing Catapult. CPIs state-of-the-art facilities provide expertise and advanced equipment for developing GMP-compliant bioprocessing technology. In addition, CPI has drawn from its extensive experience in securing public funding to help MicrofluidX secure 500k of grant funding from Innovate UK for development of the microfluidic bioprocessing platform.

CGT Catapult have more than 230 experts in the industrialisation, manufacturing and clinical adoption of cell and gene therapies, and support industry and academic partners to develop and commercialise these transformative medicines. In this collaboration, the organisation will support MicrofluidX to implement, test and optimise the microfluidics platform, utilising the technology and expertise at the CGT Catapult development centre laboratories in London.

Dr Antoine Espinet, Founder and CEO, MicrofluidX, said:

We are excited to be working with CPI and the Cell and Gene Therapy Catapult on the development of our innovative microfluidics platform. Our technology will cut the time and costs required to bring cell and gene therapies to market, improving access to these novel treatments.

Lucy Foley, Director of Biologics, CPI, said:

We look forward to working with MicrofluidX, following our successful grant application. This technology could play an important role in the future development of cell and gene therapies, and our expertise in the manufacturing of biologics will help to ensure that the technology is market-ready as quickly as possible.

Matthew Durdy, CEO, CGT Catapult, commented:

We are delighted to be supporting the development of this microfluidic bioprocessing platform, technology which shows significant promise for scaling up cell and gene therapy manufacture. The Cell and Gene Therapy Catapult is looking forward to working with MicrofluidX and CPI, innovating together to overcome barriers in the UK industry.

About CPI

CPI works with partners to translate inventions into products and processes that enhance health and wellbeing, protect and improve our environment and increase productivity across industries. With a deep understanding of technology fore-sighting, innovation processes and funding, outstanding technical expertise and industry-relevant assets, we enable the accelerated development of transformational products and processes that have the potential to disrupt and revolutionise markets. We also engage in incremental technological innovation that allows established products and processes to be optimised for better performance and efficient manufacture. Through the breadth of our technology platforms, we support our partners across many diverse markets, including pharmaceuticals, speciality chemicals, food and drink, electronics and transportation. http://www.uk-cpi.com

About the Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 230 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.

About MicrofluidX

MicrofluidX is tackling the problems of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell and gene therapy. Its automated, closed technology allows biologists to easily carry out process development by running dozens of cell culture conditions in parallel with extreme process control, and to scale up seamlessly up to several billion cells for manufacturing at a fraction of the current costs. https://www.microfluidx.co.uk/

Read the original here:

CPI, the Cell and Gene Therapy Catapult and MicrofluidX announce development of technology to rapidly scale up cell and gene therapy manufacture -...

Expression Therapeutics Announces Bill Swaney as VP of Manufacturing and the Construction of Cell and Gene Therapy Manufacturing – BioSpace

Posted on by

ATLANTA, July 30, 2020 /PRNewswire/ --Expression Therapeutics has announced the appointment of Bill Swaney as the Vice President of Manufacturing. He comes to Expression Therapeutics from the Cincinnati Children's Hospital Medical Center where he was the Director of the Vector Production Facility & Viral Vector Core. Mr. Swaney is an internationally recognized expert in GMP cell and gene therapy manufacturing and has conducted over 70 GMP production runs for academic and commercial clients.

"We are pleased to welcome Bill, a pioneer in cell and gene therapy manufacturing, to Expression Therapeutics. Under his leadership, we now have a complete manufacturing team, making us one of the few biotechnology companies with its own therapeutic pipeline and in-house manufacturing, with the capability to provide CDMO services to commercial clients," said Mohan Rao, Ph.D., CEO of Expression Therapeutics.

Expression Therapeutics has also announced today the construction of a 43,000-sq ft manufacturing facility in Cincinnati, Ohio. The facility will manufacture lentiviral (LV), retroviral (RV), and adeno associated viral (AAV) GMP vectors,with a mix of 30-180 liter runs in cell stacks and up to 1,000 liter runs in bioreactors, and will have the capability to manufacture up to 100 GMP vector products per year. Additionally, it provides the necessary infrastructure to fulfill Expression Therapeutics' ex vivo cell processing and recombinant protein production needs. Expression Therapeutics is using prefabricated PODs from G-CON Manufacturing, Inc. for its ISO Class 7 cleanroom suites.

"We decided to utilize advanced pre-built modular cleanrooms from G-CON to accelerate our buildout and commence vector manufacturing this year. With vector GMP manufacturing backlogs today typically exceeding 18 months, we wanted to bring on additional capacity as soon as possible to serve clients," said Bill Swaney, Vice President of Manufacturing for Expression Therapeutics.

Expression Therapeutics is a biotechnology company based in Atlanta and Cincinnati. The current therapeutic pipeline includes advanced gene therapies for hemophilia, neuroblastoma, T-cell leukemia/lymphoma, acute myeloid leukemia (AML), and primary immunodeficiencies such as hemophagocytic lymphohistiocytosis (HLH).

For manufacturing inquiries, please contact Bill Swaney at wswaney@expressiontherapeutics.com.

For all other inquiries, please contact:Ashley WalshDirector of Corporate DevelopmentExpression Therapeutics1860 Montreal RoadTucker, Georgia 30084awalsh@expressiontherapeutics.com+1 312.637.2975

View original content to download multimedia:http://www.prnewswire.com/news-releases/expression-therapeutics-announces-bill-swaney-as-vp-of-manufacturing-and-the-construction-of-cell-and-gene-therapy-manufacturing-301103194.html

SOURCE Expression Therapeutics

See more here:

Expression Therapeutics Announces Bill Swaney as VP of Manufacturing and the Construction of Cell and Gene Therapy Manufacturing - BioSpace

Navigating Complexity in Oncology Cell and Gene Therapy Clinical Trials – Clinical OMICs News

Posted on by

As more knowledge is revealed about the genetic underpinnings of cancers, cell and gene therapies (CGT) are playing an increasingly important role in treating oncology patients.

The development of chimeric antigen receptor T cell (CAR-T cell) therapiessuch as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel)and their success in combating hematological malignancies, has paved the way for a surge in investment in CGT, especially adoptive cellular transfer (ACT), in oncology. While in the beginning, we were somewhat limited to CAR-T monotherapies anchored in single antigen targets for CD19-expressing lymphomas and leukemias, research has grown to include expanded and multi-targeting modalities, including additional adoptive cell therapy immune cell vehicles (e.g. NK cells, macrophages, dendritic cells, CD 4+ T cells, etc.). Therefore, it is likely CAR-T cells may be used as both monotherapy, or in combination with novel agents.

Estimates as of February 2020 suggest there are more than 1,000 CGT trials globally, with nearly 600 of those in oncology. Whats more, recent market intelligence projects the global CGT market will continue to rise at a compound annual growth rate of 36.25 percent between 2019 and 2025. The investment in oncology emphasizes the importance of developing innovative and accelerated ways to deliver CGT trials and address the challenges of scaling to commercialization. As such, the demand for understanding how to solve these challenges will continue to increase over the next decade.

The success of CGT has transformed the delivery of clinical trial services, requiring the design of new workflows, processes, and tools to address the nuances and complexities of how CGT trials are executed compared to traditional trials. As the industry evolves, the next generation of adoptive cellular transfer products will move closer to becoming a front-line treatment, as opposed to being limited to relapsed or refractory patients, and will have improved safety and durability of response. Developing improved investigational products requires the use of laboratory services to better identify targets and biomarkers, such as advancing polymerase chain reaction (PCR) and liquid biopsy techniques.

Here, we outline the challenges in designing and executing oncology CGT clinical trials and potential solutions to those complexities.

Challenges in designing and executing CGT clinical trials

Cell therapies are living medicines, with many being autologous, requiring each patient sample to have its own process. This personalization creates a more complex development cycle than other biologic drugs. One of the main challenges in this approach is developing well-defined characteristics or attributes (i.e., cell phenotype of functional measurements) that are well correlated with outcomes for these investigational products, as there are many causes of variability. For example, there may be differences in cells from donor to donor, which can make it difficult to determine which factors drive efficacy and safety. Notably, with CAR-T therapies, significant side effects include cytokine release syndrome (caused by the production of a large number of inflammatory molecules by CAR-T cells) and neurotoxicity, both of which are related to therapeutic efficacy. New characteristic safety profiles could emerge, which need specific considerations on how to manage patients.

Moreover, as biotech companies start to move toward solid tumor targets, the treatment of patients with advanced solid tumors has become more dependent on tissue biomarkers to help guide management decisions. As a result, the ability to obtain tissue for the production or expansion of cell therapies adds another burden. Further, targeted therapies are associated with superior clinical outcomes, but to obtain updated biomarkers and targets, large biopsy specimens are often needed. This is not always feasible, either because lesions are not safely accessible to a surgeon or an interventional radiologist, or because the patient declines further invasive procedures.

Allogeneic therapies, or those using cells from healthy donors, may avoid some complexities of modifying a patients own cells. For example, Gracell Biotechnologies recently presented preliminary results of a first-in-human, universal CAR-T therapy, GC027which targets CD7 on malignant T cellsfor treating adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia. The ability to produce hundreds of viable cells for multiple infusions can overcome issues related to the time it takes to manufacture T-cells, costs to generate a product for each patient, failures in the ability to generate a product from a patients immune cells, and the heterogeneity of T-cell products. However, allogeneic approaches will need to circumnavigate challenges in tissue-matching, which means that human leukocyte antigen typing becomes important in many cases, possibly limiting the target population.

Gene editing and other engineered products, such as T-cell receptor (TCR)-engineered T cells, to treat cancer, are entering into safety and feasibility trials. For example, the first clinical trial using CRISPR-Cas 9 editing to engineer T cells in patients with refractory cancer launched in the fall of 2019. These experimental technologies will raise similar challenges as they move forward through early phase clinical trials.

Conclusion

Over the next 10 years, we will continue to witness significant advances and excitement as CGT saves the lives of patients. First, the industry will conquer the challenges created by the tumor microenvironment, opening opportunities to successfully tackle a broader range of solid tumors. Second, new strategies will emerge to improve the manufacturing and delivery of autologous and allogeneic therapies, improving cost-efficiency. These future advances will be assisted by enhanced diagnostic assays and other tests to improve our understanding of targeting and treating cancer.

Originally posted here:

Navigating Complexity in Oncology Cell and Gene Therapy Clinical Trials - Clinical OMICs News

Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results – BioSpace

Posted on by

BOSTON and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 6, 2020, at 8:00 a.m. ET to review business updates and its second quarter 2020 financial results.

A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at http://www.orchard-tx.com. The conference call can be accessed by dialing (866) 987-6504 (U.S. domestic) or +1 (602) 563-8620 (international) and referring to conference ID 7392139. A replay of the webcast will be archived on the Orchard website following the presentation.

About Orchard

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Contacts

Investors

Renee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

View original post here:

Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results - BioSpace

Genprex CEO Participates in a Second-Round Live Interview on the Big Biz Show – Business Wire

Posted on by

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that its Chairman and Chief Executive Officer, Rodney Varner, has participated in a second-round live interview on the Big Biz Show, an emmy-award winning nationally syndicated TV and radio show. A replay of the interview is available for viewing on the Companys website at https://bit.ly/2Esvq05.

During this interview, Mr. Varner discusses:

The Big Biz Show covers current business events, internet-related issues and other hot topics in the business world. The Big Biz Show is seen and heard in over 100 million broadcast TV homes, 150 radio stations in the U.S. and in 175 countries. The Emmy Award winning show was named by TALKERS Magazine as one of the Top 10 Most Influential Financial Shows.

The Big Biz Show can be seen and heard every weeknight on YouTOO America Television Network at 8 p.m. ET, the following morning at 7 a.m. ET, and every weekday on BizTalk Radio at 2 p.m. ET. Additionally, the show can be accessed digitally by visiting BizTVClub.com, where you can watch the Big Biz Show every weeknight at 9 p.m. ET.

To watch Mr. Varners first live appearance on the Big Biz Show in June 2020, visit Genprexs website.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Companys lead product candidate, Oncoprex, is being evaluated as a treatment for non-small cell lung cancer (NSCLC). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Companys future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of GPX-001, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of GPX-001 and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

See the rest here:

Genprex CEO Participates in a Second-Round Live Interview on the Big Biz Show - Business Wire

The adventure app Randonautica has led users to dead bodies, haunted houses, and other bizarre destinations – Boing Boing

Posted on by

Living through a pandemic may not feel predictable, but your quarantine routine probably does. However, even beyond lockdown life, the world can be "close to deterministic," according to the Fatum Project theory. "All things in the world are causally connected and everything that happens, including our thoughts, is usually determined by the sum of all environmental factors."

Randonautica is an app that borrows from the Fatum Project's research to break away from the probability-tunnels our everyday choices create. Using a quantum number generator to send users to a set of mysterious coordinates, Randonautica has become a "fully functional reality-tunnel creating machine that digs rabbit holes to wonderland." Perhaps it sounds enchanting, but for some, the trip to wonderland can be unnervingly ominous.

If you're not into quantum physics and philosophy, this may seem like a jumble of nonsense. Maybe you are into quantum physics and philosophy, but it still sounds like a jumble of nonsense. Either way, I'll offer a quick summary of what helped me make sense of some of the internet's "Randonauts" adventures and get to the fun (spooky) stuff.

No matter what choices we make, there are simply some places we can never be because our chain of decisions will never lead us there. The app can measure different magnetic fields around you called voids, attractors, or a pseudo (more on those later). Meshing the physical energy, or lack of it, around you with the power of the human mind can show you something you would never have found otherwise.

Many users of the app have generated trip reports saying they got what they wanted. Before beginning a trip, the app asks the user to "set an intention." Popular intents are somewhat mystical, like "adventure," "peaceful," or asking for some sign from the universe. A large portion of Randonauts say they were led to hidden waterfalls, lush greenery, or did indeed receive a message from the universe.

My intention was "Glitch", kind of looking for a sign to know if the reality we live in is a simulation. Guess I found it. from r/randonauts

More recently, though, the app's adventurous mix of technology and spirituality has taken on a somewhat sinister reputation after @ughhenry posted a video on TikTok of their coordinates leading to a suitcase on a beach with two dead bodies stuffed into it.

Something traumatic happened that changed my life checkkkk @natthecvt ##fyp ##viral ##crime ##murder ##randonautica ##randonauting ##scary ##washington

Creepy, scary, horror, synth, tension - Sound Production Gin

In a live stream after the video was posted, the TikToker reportedly said their intention was "travel" and had chosen an attractor to generate their quantum points. Attractors are areas with dense quantum points and have high human mind-matter interactions. When the video appeared on my TikTok For You Page, I thought the build-up would be anticlimactic. If anything, a hoax, but Seattle police confirmed the app had led the teens to a crime scene, according to Heavy.

The Randonauts Reddit page has existed since March of 2019 and currently has 121,000 members. Since the viral video, Randonautica has gained a tremendous new following, many who have ditched the mystical for the macabre.

In another unsettling video, a young woman's trip report shows her sobbing while explaining that her intention of "death" led her to a man who lay dying in his wife's arms after being shot by the side of the road.

this just happened in aurora colorado. please do not go randonauting, you never know what youre going to come across. ##randonautica

original sound - mykenarae

One user says they went Randonauting on their daily walk and wanted to manifest "something depressing." Along the route they take every morning they suddenly found this:

So I used to Randonautica app again this morning on my walk (same route i take every time), my intention was set on something "depressing". Half hour later I find this graffiti art piece on a wall I walk pass at least 4 times during my normal walk. I've never seen it before. from r/randonauts

A group of friends asking for something creepy came across this worrisome find:

Tried randonauting for the first time yesterday. Intent was creepyand bag. Our coordinates landed in the woods behind an old farm where we found strange rock piles, tires, and a bag that contained about 20 different ids, credit cards and residency cards belonging to different women. Creepy bag?! from r/randonauts

Initially, it would seem the ID cards belong to murder victims, but the Randonaut who discovered them decided they belonged to women using fake IDs as a way to immigrate.

One user believes they came across something paranormal on a night drive to see something interesting. They say that they arrived at a house with a single red light bulb illuminating a tall figure staring at them from the end of the driveway. They say that since then, they have been receiving calls and voicemails from unknown numbers. The app asks that you do not go Randonauting at night.

This Randonauter says they captured evidence of the paranormal (zoom into upper left window):

Intention: ghost from r/randonauts

Some Randonauts have less chilling supernatural finds. This couple asked for something "otherworldly" and arrived at a celestial underground scene:

Set intention for "otherworldly" GPS took us to a point on a very busy street near our house. We heard faint, bizarre music and my boyfriend pointed out the bike path that ran under the road below us. Meandered down to find this! from r/randonauts

This one found God:

First Time - I was looking for God. Took me to the top of a hill overlooking the city and etched deeply in the dirt read Jesus Christ is God hahaha from r/randonauts

Finally, some intentions manifest in the way a tricky genie would make your wish come true.

This Randonaut had the intention of "safe," as in "safety," and was brought to a literal safe:

Intention: safe (as in safety) - it brought me to a literal gd safe from r/randonauts

This couple asked for Ariana Grande:

My Intention: Ariana Grande from r/randonauts

These examples are a tiny portion of the meaningful coincidences and strange happenings the Randonaut subreddit offers.

However, with the increased appetite for the dark side of Randonauting, I've seen multiple stories about some eerie finds such as smashed phones, women's clothing strewn about, children's toys, and sometimes even bones. Another frequent occurrence is users saying the app led them somewhere a disturbing death previously took place. These findings are all in line with what the users said were their intentions.

Some Randonauts are actively seeking something on the dark side, but even those who aren't may manifest something called a "despair meme". Randonautica defines it as "an idea, behavior, or style that spreads by means of imitation from person to person." If a user only sees Randonauting negatively, their mind will take those connections and apply it to their own experiences with the app. This may contribute to the influx of unsettling trip reports.

If you are still skeptical, well, why wouldn't you be? With the clout that comes with a good ole viral video, it makes sense that some users would put out a false narrative. For example, one video showed two young men who say the app led them up a narrow hillside where they could not turn around. When they get out of the truck, a small boulder comes hurtling down the hill to the road. After watching a second time, it became clear that there is a third person behind a tree, chucking the rock down. This post was one of the only ones I could find with others agreeing it was fake. Otherwise, many of the creepier posts have arguments in the comments between believers and skeptics.

If Randonauting manages to break the user out of probability tunnels, chaos theory would say that the one small change can make the system behave entirely differently. The invitation to new possibilities coupled with any synchronicity the human mind could gather offers some validity to much of the Randonauts community trip reports.

It seems to me that where you go Randonauting will also profoundly influence your results. I have tried about 26 times intending to find a stray dog I could adopt and call Chubba or Beef Wellington, but exploring suburban areas doesn't seem optimal for this. Maybe that was also a bit too specific, but I had hope after hearing stories of people finding their new pets with the app.

To generate your trip, Randonautica asks you to choose a void, an attractor, or a pseudo. These types of points influence where you will go and what you will find. A void has a sparse number of quantum points, meaning it does not have much influence by human mind-matter interaction. According to Randonautica, "the more sparse the void, the stronger its power is, and the higher significance it has towards your intention." When I chose to venture towards a void, it would take me to places like Mulholland Drive or hiking trails.

An attractor is the opposite of a void. When I chose trips to an attractor, I would end up at apartment complexes, homes, or other properties I couldn't go in.

Pseudos are a truly random point that has you explore your blind spots. You are also able to choose what type of generator to use. Choosing ANU means a machine at the Australian National University generates numbers based on "fluctuations in the magnetic field of virtual particles in a vacuum." The temporal option provides random numbers generated by a CPU.

I do believe that the truth is sometimes stranger than fiction. Falling down the Randonaut rabbit hole has opened my mind to an alternate thought process that is open to randomness and meaningful coincidences. Perhaps, that in itself invites an entirely new set of possibilities I would never have found otherwise.

[Although the above paragraph was supposed to be my last, I had to send Boing Boing a new bit of last-minute information. After I last went Randonauting Wednesday morning, for my full-figured new pet, a friend reached out to ask if I could foster her Rottweiler, Helga. I said yes.]

Image: @ughhenry / TikTok

Go here to read the rest:

The adventure app Randonautica has led users to dead bodies, haunted houses, and other bizarre destinations - Boing Boing

The Irish Times view on Brexit: the risks have not gone away – The Irish Times

Posted on by

The coincidence of the hit to the economy from Covid-19 and the risk of the United Kingdom leaving the European Union trading regime at the end of year without a deal are, correctly, concerning the Government. Briefing papers drawn up for Minister for Foreign Affairs Simon Coveney warn of the difficulty of households and businesses absorbing a second shock, in the midst of the ongoing economic impact from Covid-19. It is a threat, in particular, for rural Ireland.

It is hard to believe that, in the middle of the Covid-19 crisis, we might still be facing a kind of hard Brexit at the end of the year. The UK has already left the EU, of course, but is in a one-year transition period when it remains in the EU trading bloc and many associated agreements continue in place. This all ends on December 31st and the UK decided not to extend the transition period.

Even if there is a deal, there will be disruption for Irish companies trading with the UK, involving new bureaucracy and, initially, quite probably delays and some uncertainty.

For Northern Ireland, a special regime outlined in a protocol agreement has to bed in and there is, as yet, a lack of detail as to how this will operate in practice.

If there is no new trade deal between the UK and EU, the damage to the Republics trade with Britain would be worse and the Northern Ireland protocol will be more difficult to implement.

A lot of work went into planning for a hard Brexit last year, so some preparation has been done. The problem is that since then the economy has been faced a massive economic shock, depleting the resources and leeway in the finances of businesses and some households. As the civil service briefing warned, Ireland is now facing into Brexit from a fundamentally different economic starting point than for a no-deal Brexit in 2019.

While the officials are correct that protecting the 85 billion trade link with the UK is important to our economic future, short-term damage would inevitably worsen in the event of no trading deal being reached.

In particular, the imposition of tariffs on trade, particularly on food products, threaten a big hit to Irish food exporters and higher prices in the shops here. Beef exports, and thus cattle farmers, are particularly exposed.

The Covid-19 crisis is impacting heavily on parts of rural Ireland which, unlike the main cities, do not have many other big employers to soften the blow from losses in tourism and hospitality. Another sector vital to rural Ireland agriculture and food faces the biggest threat from Brexit. We can only hope that, even if late in the day, some kind of Brexit trade deal is agreed which, as the briefing to the Minister concludes, will require movement on both sides, but more particularly from the UK.

See the original post:

The Irish Times view on Brexit: the risks have not gone away - The Irish Times

‘Brexit can be reversed!’ Whinging Labour MP’s claim UK will rejoin EU laid bare – Daily Express

Posted on by

The UK left the EU at the end of January this year after Prime Minister Boris Johnson's resounding victory in the 2019 general election. As the country was preparing for a new chapter, Labour MP Ben Bradshaw told German press that the UK will be back. He made the claim just weeks before the UK finally left, signalling that some Remainers hadn't given up the fight. He said in January: Everything is possible. And in politics you should never say never anyway.

Unfortunately, re-entry into the EU is not an issue in the short term.

You just have to take note of the current facts in British politics.

But once the difficult decisions that Brexit brings are on the agenda, the debate will change.

That could eventually lead to full membership again.

Mr Johnson's victory in the 2019 election made Brexit a formality and this led Mr Bradshaw to criticise his former party leader, Jeremy Corbyn.

He blamed Mr Corbyn not just for the election drubbing, but also Brexit.

Mr Bradshaw continued: He is not only responsible for the crashing defeat of the Labour Party in December.

It is also due to Jeremy Corbyn that the 2016 EU referendum was lost.

In the middle of the referendum campaign, he took two weeks off on vacation.

At the time, he was not fully committed to remaining in the EU.

READ MORE:How EU was warned 'you will live to regret appointing Juncker'

Figures in the Labour Party aren't the only people who think the UK could rejoin the EU one day, as prominent leaders in Brussels have made similar predictions.

Former President of the European Commission Jean-Claude Juncker laid out how he believed the UK could reverse Brexit and rejoin the EU.

He made the provocative claim in 2017 as the UK prepared for withdrawal talks, a year after the country opted to leave the EU. Mr Juncker told reporters that he regretted Britains decision to leave but held out hope that it would return in the future.

DON'T MISSMichel Barnier's critical trade talk mistake: 'He's backtracked!'[INSIGHT]Brexit trade talks: Michel Barnier's double U-turn revealed[ANALYSIS]EU's anger at 'saboteur' Boris Johnson in Brexit talks unmasked[INSIGHT]

He said: I dont like Brexit. I would like to be in the same boat as the British. The day will come when the British re-enter the boat. I hope.

A senior aide later said the option of Britain returning to the EU will always be open and outlined various ways in which it could happen.

They added: There are different ways you can join. You can be a full member, you can be a partner, you can be related to us in the customs union, or through a trade agreement.

Originally posted here:

'Brexit can be reversed!' Whinging Labour MP's claim UK will rejoin EU laid bare - Daily Express

Brexit and beyond: trade mark protection strategies in an uncertain global marketplace – Lexology

Posted on by

Brexit planning for your trade mark portfolio needs to be back on the agenda particularly after the delays caused by coronavirus to get the most cost-benefit out of the current regime, before the end of the transitional period.

This was the message delivered by Womble Bond Dickinson's James Love and Rose Smalley (both Leeds, UK) who, along with WBD colleague Nicholas Hawkins (Baltimore, US), and Scott Schwartz, General Counsel at Dansko, presented at the Association of Corporate Counsel 12th Annual In-house Counsel Conference, which took place virtually on 28 and 29 July 2020.

The topic of their presentation was "Brexit and Beyond: Trademark Protection Strategies in an Uncertain Global Marketplace", and the session included a series of audience polls concerning various issues rights-holders will face for IP protection coming out of Brexit.

It was revealed that 82% of respondents knew that changes were coming to trade mark protection as a result of Brexit, but that they had not put into place any plans to deal with these changes.

Rose noted that these results did not seem all that surprising; in the years since the referendum result, many updates have circulated about the potential impact of Brexit on IP protection but, in recent months (and for good reason) Brexit has taken a back-seat whilst the world grapples with cCoronavirus. Further, James noted that there has been little urgency in putting those plans in place at least not until the recent emphasis by the United Kingdom (UK) government that it does not intend to seek another extension for the trade agreement negotiations.

Attendees surveyed identified a potential loss of rights in the UK as their primary concern arising from Brexit.

James reiterated that, whether or not a trade agreement with the European Union (EU) could be achieved, the UK would unilaterally provide for continued protection in the UK of local rights previously protected under an EU trade mark. This will be done by granting automatically and free of charge a new comparable UK trade mark right after the end of the transitional period. This new right will ensure that rights-holders are given continuing protection in the UK, whilst their EU trade mark registration continues to protect their mark in the remaining 27 member states. James explained the new UK right will inherit the filing (or priority/seniority) date from the EU registration, but will be a wholly independent right, capable of being licensed or assigned separately from the EU trade mark.

Another issue high on the agenda was 'squatters', i.e. third parties who might seek to register a mark in the UK before the EU rights-holder has the opportunity.

As well as receiving a new comparable UK trade mark right in respect of each EU trade mark registration, James noted that applicants for EU trade mark rights (i.e. where the right has not achieved registration by the end of the transitional period) will have a nine-month priority period to file in the UK. This gives legitimate right-holders a longer period than usual (priority claims are normally six months), to prevent squatters from registering conflicting rights in the UK, but does come at the additional cost of applying for a separate UK trade mark.

Rose added that it would be sensible to keep a close eye on how EU trade mark applications are progressing particularly given the delays and backlog that have been caused at the EU Intellectual Property Office (IPO) by closure of its headquarters due to the impact of COVID-19. It is obviously preferable to obtain your EU trade mark registration before the end of the transitional period, in order to avoid the additional UK trade mark filing fees and obtain your comparable UK right for 'free' but this window of opportunity is due to close shortly, given the normal timescales for registration at the EU IPO.

The vast majority of respondents suggested that the UK should adopt international exhaustion after the end of the transitional period, allowing goods to be imported into the UK without restriction.

James noted that the issue of exhaustion is very much still on the negotiating table. The only agreed point is that rights which are exhausted as at the end of the transitional period i.e. rights protecting goods already in circulation in the European Economic Area (EEA) as at that date will remain exhausted. However, this leaves open the issue of exhaustion of rights protecting goods that enter into circulation either in the UK, or the remaining 27 EU Member States after the end of the transitional period.

Rose noted that a model of international exhaustion under which right-holders would be required to justify why genuine goods placed on a market elsewhere (by it or with its consent) should not be permitted to be imported into the UK is generally perceived to be more consumer-friendly, by increasing competition (amongst the right-holders and lawful importers), thereby driving prices down. This would be a significant departure from the regional exhaustion (i.e. free movement of goods legitimately placed on the market in the EEA only) which the EU (including UK) currently operates, but would be in line with the UK's wish to strike out as an open and global trading nation, particularly given pressures from other potential trading partners (such as the US).

Overall, attendees were not in agreement over whether Brexit presented opportunities for the UK, and/or the US, but it was noted that remaining uncertainties are likely a significant reason for the differences in opinion. The overriding message was to "keep calm and carry on" and to start implementing plans now for trade mark protection in the EU and UK.

Go here to see the original:

Brexit and beyond: trade mark protection strategies in an uncertain global marketplace - Lexology

North-South body meets in Dublin to discuss coronavirus and Brexit – The Irish Times

Posted on by

The first meeting of the North South Ministerial Council (NSMC) since before Northern Irelands powersharing administration collapsed is taking place on Friday.

Taoiseach Michel Martin and members of his cabinet will meet the Norths First Minister Arlene Foster and Deputy First Minister Michelle ONeill and their colleagues for talks on Covid-19 and Brexit at Dublin Castle.

It allows the new Government and the restored Northern Ireland Executive to converse formally for the first time and exchange views on issues of mutual interest and concern.

This is the first plenary session since November 2016 of a body set up under the Belfast Agreement to deepen co-operation across the island.

The Taoiseach said: I will also take the opportunity to emphasise the Governments full support for preserving and strengthening North-South co-operation and the Governments commitment to ensuring that the New Decade, New Approach Agreement is implemented in full.

The Government is focused on working with the Executive through the North South Ministerial Council to deliver projects that benefit people across the island, including greater connectivity between North and South; investing in the North West region and in border communities and supporting reconciliation as an integral part of the peace process.

Ms Foster is expected to share a platform with the Deputy First Minister in a post-meeting press conference for the first time since a row soured relations between the pair.

Ms ONeills attendance at a veteran republican Bobby Storeys funeral in west Belfast, despite restrictions on numbers due to coronavirus regulations, angered unionists.

Police are investigating possible breaches of social distancing rules by mourners as the cortege was brought through west Belfast.

Ms ONeill has stood by her decision to go to the service but did say sorry to families bereaved during lockdown for any hurt caused by scenes of hundreds of people lining the route. - PA

Read the original:

North-South body meets in Dublin to discuss coronavirus and Brexit - The Irish Times

French minister echoes Theresa May over Brexit with ‘no deal better than a bad deal’ warning – The New European

Posted on by

PUBLISHED: 12:15 29 July 2020 | UPDATED: 12:15 29 July 2020

France's European affairs minister Clement Beaune. Photograph: European Commission.

Archant

A French minister has echoed Theresa May in warning that no deal is better than a bad deal for protecting European interests.

Email this article to a friend

To send a link to this page you must be logged in.

Become a Supporter

Almost four years after its creation The New European goes from strength to strength across print and online, offering a pro-European perspective on Brexit and reporting on the political response to the coronavirus outbreak, climate change and international politics. But we can only continue to grow with your support.

The countrys European affairs minister Clement Beaune said it will continue to take a tough line on Brexit talks, saying that the EU would not accept a deal at any price.

The new minister has been described as Emmanuel Macrons Brexit whisperer, with reports suggesting the French president is keen to use Britains departure an opportunity to make Europe stronger.

Beaune said that he believed a prospect of a deal with the UK is still possible, and said that a deal was the best outcome, but he warned they would take a tough stance on issues such as the fisheries - which remains a sticking point for a deal.

We will not accept a deal at any price, he told France Inter radio.

Better no deal at all than a bad deal, he added.

Beaune, however, accepted that a no-deal situation would not be good for the EU, but that the interests of the union and his own country was important.

Lets not kid ourselves, if there is no deal, it will be a difficult issue, Well have to organise a response for sectors like fisheries. Support our fishermen financially. Were not there yet.

He added representatives of the EU would not be intimidated by the game that British negotiators were playing.

During Theresa Mays tenure as leader she regularly warned the EU that a no deal situation is better than a bad deal.

Almost four years after its creation The New European goes from strength to strength across print and online, offering a pro-European perspective on Brexit and reporting on the political response to the coronavirus outbreak, climate change and international politics. But we can only rebalance the right wing extremes of much of the UK national press with your support. If you value what we are doing, you can help us by making a contribution to the cost of our journalism.

Excerpt from:

French minister echoes Theresa May over Brexit with 'no deal better than a bad deal' warning - The New European

China’s ambassador accuses UK of ruining post-Brexit relations with tough stance on Hong Kong – iNews

Posted on by

Chinas ambassador has warned that the UK will need to forge closer links with the country after Brexit as he attempted to persuade the Government to take a less aggressive approach on issues such as Hong Kong, Huawei and Xinjiang.

Liu Xiaoming said on Thursday there would be consequences for recent British actions, confirming that China is planning to block Hong Kong residents from travelling using their British National (Overseas) passports. It comes as multiple democracy activists have been banned from standing in the territorys election under new national security legislation.

He told a press conference: China respects UK sovereignty and has never interfered in UKs internal affairs. It is important that the UK does the same.

When Brexit is completed and Covid-19 is over, there will be unlimited prospects for UK-China co-operation in areas of trade, financial services, science and technology, education and healthcare. It is hard to imagine a global Britain that bypasses or excludes China. Decoupling from China means decoupling from opportunities, decoupling from growth and decoupling from the future.

Mr Liu claimed that the UKs decision to offer residency to 2.9m Hongkongers and scrap its extradition treaty with the territory seriously disrupted the security and prosperity of Hong Kong.

Asked if he was threatening Britain, the ambassador replied: We made no threats, we threatened nobody, we just let you know the consequences If you treat China as a hostile country, you will pay the price. He directly criticised Conservative MPs who have pushed for tougher action against China, saying they cling to the Cold War mentality.

He also confirmed that in retaliation for the British decision to allow holders of BNO passports to settle in the UK from next year, Chinas government may stop recognising the documents as a valid travel pass. Mr Liu said: We have to take our measures not to recognise the BNO passport as a valid travel document.

The press conference concluded with a series of propaganda videos designed to refute findings by Western governments that China has been herding Uighur Muslims from Xinjiang province into prison camps for re-education. The clips showed alleged terror attacks by Uighurs, followed by upbeat footage supposedly depicting Xinjiang residents who have found new jobs after spending time in the camps.

Asked whether China would allow independent inspectors to visit the camps, which are believed to be used for forced labour, Mr Liu said that any investigation would violate Chinas sovereignty.

More:

China's ambassador accuses UK of ruining post-Brexit relations with tough stance on Hong Kong - iNews

Managing the supply chain post-Brexit – New Electronics

Posted on by

With the launch of the UK governments information campaign urging businesses to prepare for the Brexit transition next year, significant changes and opportunities can be expected.

One key issue in a post-Brexit world, will be the risks of border crossing delays between the United Kingdom and the EU. Businesses, according to Tom Holland, Territory Sales Manager, UK and Ireland at Sigfox, need to act now to prepare and to strengthen supply chain visibility.

On 1 January 2021, the UK will have a new relationship with the EU and with the clock running down, the most likely outcome is that the UK will not enter into a new free trade arrangement with the EU.

The UK is already behind in its preparations and this is where greater visibility of the supply chain is a must to ensure a smoother transition, explains Holland.

Critics of the UK government suggest that it has been showing wilful ignorance and is ill-prepared to operate a functioning customs border.

We didnt have enough time to put in place the infrastructure, people, and systems we needed before COVID-19 [and] we certainly dont now, said one.

So new trade barriers are likely and for businesses this will present a number of new challenges.

Those barriers could take many forms, such as divergence of regulations, introduction of tariffs, or goods quotas. What is clear is that with the introduction of new trade barriers, the risk of delays in moving goods across the border in either direction increases significantly, says Holland.

The impact of border crossing delays will vary from industry to industry. Industries that utilise just-in-time manufacturing processes, and industries that trade in perishable goods such as food and medicine, are likely to feel the effects of border crossing delays more than most.

The options available to businesses will depend on the type of cross-border trade, according to Holland. How can they prepare for those delays? Invest in new facilities to stockpile? Plan alternative supply routes if primary routes become congested? Identify possible local supply

alternatives? Renegotiate contracts to make special provisions for border delays? Build contingencies into to the supply chain?

What cuts through all of those options is a need for greater visibility and greater access to data. To mitigate border crossing delays, businesses need real time visibility of those delays to inform their contingency plans.

Lack of end-to-end visibility of the supply chain is not just a Brexit issue though; it is arguably the greatest challenge facing enterprise supply chains in 2020, says Holland. We need to move to an efficient and optimised, data-driven approach, when it comes to trade.

Can the IoT help?

The Internet of Things (IoT) has the unique ability to capture vast amounts of extremely valuable data, helping businesses better understand the behaviour of people, environments and assets to give a real-time holistic view of the entire supply network says Holland.

By implementing connected devices across the supply chain, businesses could gain a vast array of data that not only can give them real-time data on border crossing delays and the impact to the supply chain, but could fulfil regulatory requirements, and offer granular insights into the efficiency and real time operation of their networks.

The possibilities with regards to the data that IoT can extract are vast; businesses can gain additional data and insight of routes travelled, warehouse delays, monitoring of goods in transit, and even the ability to expedite customs requirements by verifying the provenance and authenticity of goods, or by confirming that a container hasnt been opened or modified from the time it was packed.

According to Holland, customers are already reaping the benefits of the IoT and the connectivity provided by platforms like Sigfox.

For example, real-time alerts about delays and transport conditions has enabled Michelin to reduce transit stock by 10%, increase Estimated Time of Arrival (ETA) by 40% and reduce Out of Stock (OOS) situations due to exceptional circumstances by a quarter.

We are seeing increasing interest across geographical locations, including the UK, via our secure sensor network operator, WND UK. We are also seeing an upsurge of demand across Europe, especially among those nations trading with the UK.

This tide of innovation is beginning to deliver measurable results, suggests Holland.

Deutsche Post DHL Group has outfitted about 250,000 DHL roll cages with Sigfox smart trackers giving it powerful levels of visibility of the essential and valuable roll cages which are used to transport large volumes of parcels.

The IoT is gradually beginning to transform and digitise the global supply chain, providing companies with unprecedented visibility into their own operations.

The accelerating pace of change, and the uncertainty and potential disruption to cross border supply chains that Brexit may bring, means that businesses will increasingly need to be on-board, and up-to-speed in order to maintain competitive advantage, says Holland.

Just a few years ago, full supply chain visibility was just a pipedream now it is a rapidly approaching business fact.

Originally posted here:

Managing the supply chain post-Brexit - New Electronics

Scottish trade disputes after Brexit will have to be settled in the courts says Tory Minister – Daily Record

Posted on by

Boris Johnson has been accused of opening the barn door to legal challenges against Scottish food standards after Brexit by ruling out an independent process to resolve trade disputes.

The SNP has warned Scottish government policy could be over-riden after UK Ministers confirmed any Brexit trade disputes over returning EU powers will have to be fought out in the courts.

Johnsons government ramped up tensions with the SNP administration in Edinburgh by confirming there will be no arbitration body to resolve disputes in the UK internal market which is due to replace EU Single Market rules in December.

Get all the top Scottish politics news sent straight to your Inbox by signing up to our Politics newsletter.

We cover Holyrood, Westminster and local councils, with a current focus on how our governments are handling the coronavirus pandemic.

To sign up, simply enter your email address into the pink box near the top of this article.

Alternatively, you can visit our newsletter sign up-centre. Once you are there, enter your email address and select Politics and any other Daily Record newsletters that are of interest.

Johnsons government is driving legislation for the internal market though the Commons this September in a rush with just one month of consultation after the Scottish government walked away from a previous set of talks.

So far Tory Ministers have refused to issue details despite calls from devolved governments and opposition MPs for a disputes panel to resolve disagreements as powers return from the EU.

But Business Minister Martin Callanan told the House of Lords on Wednesday: I hope there wont be any disputes, but if there were they would be legal disputes and the correct forum for resolving legal disputes is through the court system.

We have no intention of setting up an alternative dispute resolution procedure when we have one of the best and most efficient court systems in the world to resolve disputes.

Earlier this month Business Secretary Alok Sharma was asked four times to commit to such an arbitration panel when he introduced proposals for a UK internal market in the Common.

But Sharma dodged the questions, telling MPs his proposals would see a power surge for the devolved governments.

But Nicola Sturgeons has called the plans a power grab and Mike Russell, the Scottish Brexit Secretary, previously signalled the Scottish Government would not co-operate with internal market rules, setting the stage for a massive legal fight.

Kirsten Oswald MP, the SNPs Westminster Deputy leader, said: The confirmation through the unelected House of Lords that the UK government has no intention of meaningfully engaging with the devolved governments for an agreed dispute resolution system, is yet another sign of the Tories total disregard for the devolved nations.

The Tory government has opened the door for companies with deep pockets to challenge Holyrood legislation if we try to maintain higher standards than Westminster post-Brexit putting at risk our key industries with the threat of the imposition of lower standard goods and produce.

Far from strengthening the devolved nations, the UK governments Internal Market plans will enable the decisions of the Scottish Government to be overridden over devolved areas such as food and agriculture in Scotland.

See the original post:

Scottish trade disputes after Brexit will have to be settled in the courts says Tory Minister - Daily Record

global next-generation surgical robotics market is dominated by a PROCEPT BioRobotics Corporation, followed by CMR Surgical Ltd. in 2019 -…

Posted on by

New York, July 31, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Next-Generation Surgical Robotics Market: Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p05948599/?utm_source=GNW

Technology Miniaturized Surgical Robotics, Autonomous Surgical Robotics, and Teleoperated Surgical Robotics Product Type Surgical Systems, Instruments & Accessories, and Services Application General Surgery, Urology Surgery, Aesthetic Surgery, Cardiology Surgery, Gynecology Surgery, and Neurology Surgery

Regional Segmentation

North America- U.S. and Canada Europe- Germany, U.K, France, Italy, Spain, Switzerland, Netherlands, and Rest-of-Europe Asia-Pacific- Japan, China, India, Australia & New Zealand, South Korea, Singapore, and Rest-of-Asia-Pacific Rest-of-the-World

Growth Drivers

Rising prevalence of chronic disorders Elevating elderly population Increasing healthcare expenditure in developing economies Increasing demand for minimally invasive surgeries Low cost of next-generation surgical robotic platforms

Market Challenges

Lack of skilled professionals Restrictive reimbursement framework in several countries

Market Opportunities

Development of low cost next-generation surgical systems Development of surgical simulators for training

Key Companies ProfiledActiv Surgical, Inc., AVRA Medical Robotics, Inc., CMR Surgical Ltd., Corindus Vascular Robotics, Inc. (Siemens Healthineers AG), Memic Innovative Surgery Ltd., Microbot Medical, Inc., PROCEPT BioRobotics Corporation, Vicarious Surgical Inc., Virtual Incision Corporation, and Virtuoso Surgical, Inc.

Key Questions Answered in this Report: What are significant technological advancements in surgical robotics and how the market for next-generation surgical robotics is expected to evolve in the future? What are the major market drivers, challenges, and opportunities in the global next-generation surgical robotics market? Who are the leading companies actively working on implementing next-generation surgical robotics technologies? What is the current revenue contribution of the different technology types, and how would it change in the forecast period? What is the current market share of each of the companies in the global next-generation surgical robotics market, and what are expected to be their contributions in 2030? What is the growth potential of the next-generation surgical robotics in region, including North America, Europe, Asia-Pacific, and Rest-of-the-World? What are the key regulatory implications in developed and developing regions for surgical robotics? How is the patent landscape evolved in the past years in the next-generation surgical robotics market?

Overview of the Global Next-Generation Surgical Robotics Market

The global next-generation surgical robotics market is anticipated to gain significant traction in the future.Several key players are engaging in developing advanced surgical robotics, testing the capabilities of miniaturization, autonomous, and telesurgery technologies.

The market for next-generation surgical robotics is at a nascent stage, with only two companies having commercialized offerings.The rest of the products by other companies are still in the investigational phase and is expected to launch during the forecast period, 2020-2030.

The factors, such as increasing awareness about the advantages of surgical robotics coupled with the improving healthcare infrastructure in several economies and increasing investments & funding within the surgical robotics domain, is expected to bolster the growth of next-generation surgical robotics market.

Global Next-Generation Surgical Robotics Market Forecast, 2020-2030The market size of next-generation surgical robotics was valued at $10.9 million in 2019. The global next-generation surgical robotics market is expected to grow at a robust rate. It is anticipated to reach $884.5 million in 2030 with a CAGR of 44.6% during the forecast period 2020-2030, primarily due to the increasing prevalence of chronic disorders, elevating the global population coupled with the geriatric population, favorable reimbursement policies in developed economies, and increasing investments to develop advanced robotic platforms. However, several factors, such as a shortage of skilled professionals and restrictive regulatory framework, are the primary obstacle hindering the growth of the global next-generation surgical robotics market.

Competitive LandscapeThe global next-generation surgical robotics market is dominated by a PROCEPT BioRobotics Corporation, followed by CMR Surgical Ltd. in 2019. The companies in this market are continuously collaborating with research institutions to expand their research capabilities to develop technologically advanced products.

In the past four years, i.e., (January 2016 June 2020), the market has witnessed 25 key developments, most of which were funding activities. Efforts are put in to introduce more technologically advanced products in the market, targeting specific unmet surgical applications. With the introduction of new and upgraded devices with enhanced capabilities, it has become increasingly possible to unlock new use cases for next-generation surgical robotic technologies.

The key players contributing to the global next-generation surgical market are Activ Surgical, Inc., AVRA Medical Robotics, Inc., CMR Surgical Ltd., Corindus Vascular Robotics, Inc. (Siemens Healthineers AG), Memic Innovative Surgery Ltd., Microbot Medical, Inc., PROCEPT BioRobotics Corporation, Vicarious Surgical Inc., Virtual Incision Corporation, and Virtuoso Surgical, Inc.

Countries Covered North America U.S. Canada Europe Germany U.K. France Italy Spain Switzerland Netherlands Rest-of-Europe Asia-Pacific China Japan India South Korea Australia & New Zealand Singapore Rest-of-Asia-Pacific Rest-of-the-WorldRead the full report: https://www.reportlinker.com/p05948599/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the original post:

global next-generation surgical robotics market is dominated by a PROCEPT BioRobotics Corporation, followed by CMR Surgical Ltd. in 2019 -...

Robotics Special Report: Vision for the Future – Packaging World

Posted on by

Advances in vision systems offer packagers one of the biggest opportunities for improving productivity. Many packaging applications make use of 2D machine vision, where grayscale or color imaging creates a two-dimensional map that allows for easy detection of anomalies or variations in part contrast. As this type of vision increasingly becomes cheaper and faster, its use in packaging continues to grow, particularly in functions associated with inspection, barcode reading, surface marking detection, and basic positional verification.

Now, with innovations in 3D vision, broader applications are becoming possible. Whereas with 2D applications, where objects being scanned must be on a flat surface and of a consistent size and shape, 3D vision gives insight into product depth and height and can therefore be used for random situations, where items are located haphazardly or stacked in a bin with varying orientation.

Read related articles from Packaging World:

Industrial Robot Growth

Big Packaging Line in a Small Footprint? No Problem if it Handles a Dozen Formats

COVID-19 Brings Increased Visibility to the Role of Robotics

Wet Wipes Case Packed via Robots at 160/min

Pick-and-Place Robots, Flow Wrapper, Fuel High-Volume Bakery

One example that capitalizes on both 2D and 3D vision is Syntegons horizontal flow-wrapper, the Pack 102, with three Fanuc robots, designed for small- to medium-sized bakeries and other food companies. At PACK EXPO Las Vegas in fall 2019, the system was demonstrated loading meal kits. Explains Syntegon, each robotic platform detects and prioritizes six independent production flows simultaneously and in sequence, operating from one HMI on the flow wrapper.

Using 2D vision and dual conveyor tracking, the first robot, a Fanuc SR-6iA four-axis SCARA robot, detects and prioritizes products from two low-friction flat-belt conveyors. The second robot, a Fanuc M-1iA delta robot, precisely detects product location from two side-by-side indexing conveyors using 2D vision. The final robot, the LR Mate 200iD six-axis articulating robot, picks product from two different bulk bins using 3D vision and places the assortment into the product infeed of the Pack 102.

Theegarten-Pactecs Vision Picker robot system uses camera recognition to feed the companys wrapping machines with delicate chocolate figures.Another newly developed system allowing for productivity increases through vision is Theegarten-Pactecs Vision Picker, a robot system with camera recognition designed to feed its wrapping machines with delicate chocolate figures. According to the company, in the past, its machines had to work with chocolate molds holding a fixed number of products. These were placed by a robot in the feed chain of the packaging machine by means of a multiple tool.

The Vision Picker, it says, eliminates complex handling of the molds. Using an integrated image processing system, individual products are now detected within the disordered product flow. Each product is individually sucked in by the robot and placed in the correct position in the infeed chain of the packaging machine. Says Theegarten-Pactec, with the Vision Picker, different product formats can be packed even more flexibly and therefore more quickly and cost effectively.

Coupled with its CWM2 wrapper, the robot can feed product at 400/min; configured with its high-performance machines, the robot can operate at a rate of more than 1,000 products/min.

Read the original:

Robotics Special Report: Vision for the Future - Packaging World

Commercial Robotics Market 2020 Opportunities, Growth Analysis, Trends and Forecast by 2026 | Northrop Grumman Corporation, KUKA AG, iRobot…

Posted on by

Market research report on Global Commercial Robotics Market 2020 with Industry Analysis, Size, Competitors, Trends and Forecast 2025.

Market Research Port offers you a comprehensive market research report on the global Commercial Robotics market. This report contains in-depth information on all the key aspects of the global Commercial Robotics market. This report contains data such as facts & figures, market research, market analysis, competitive landscape, regional analysis, and future growth prospects. The report also contains qualitative and quantitative research which gives you a detailed analysis of the global Commercial Robotics market. The report has been compiled by experts who have researched and documented all the important aspects of global Commercial Robotics market. The report authors are experienced and highly qualified, so you can trust the data provided in this report.

Get The Sample Report PDF with Detail TOC & List of [emailprotected]https://marketresearchport.com/request-sample/55401

This market research report also has data of all the important players in the industry. From their market share in the industry, to their growth plans, important information has been compiled in the report to let you get an insightful look at the leading players operating in the industry and what their strategies are. The functioning of the leading companies in the (industry name) market has a huge impact on how the market behaves. Therefore, data on these companies can also help you understand and predict how the market behaves. The competitor analysis in the report will give you a complete breakdown of all the important information you need about these top market players.

Major Companies Covered:

Northrop Grumman Corporation, KUKA AG, iRobot Corporation, Yaskawa Electric Corporation, Honda Motor Company Ltd., Omron Adept Technologies Inc., 3D Robotics Inc., Accuray Inc., Alphabet Inc., Amazon Robotics LLC

In the global Commercial Robotics market report, there is solid in-depth data on various segments as well. These segments give a deeper look into the products, applications and what impact they are going to have on the market. The report also looks at new products and innovation that can be real game-changers.

The Report is Divided into The Following Segments:

Market Segmentation by Product Types:Medical Robots, Autonomous Guided Robots, Drones, Field Robotics

Market Segmentation by Applications:Defense, Rescue and Security, Agriculture and Forestry, Medical, Marine

Regions Mentioned in the Global Commercial Robotics Market:

The Middle East and Africa North America South America Europe Asia-Pacific Middle East Oceania Rest of the World

Following Questions are Answered in This Report:

What will be the size of the global Commercial Robotics market in 2025? What is the current CAGR of the global Commercial Robotics market? Which product is expected to show the highest market growth? Which application is projected to gain a lions share of the global Commercial Robotics market? Which region is foretold to create the most number of opportunities in the global Commercial Robotics market? Will there be any changes in market competition during the forecast period? Which are the top players currently operating in the global Commercial Robotics market? How will the market situation change in the coming years? What are the common business tactics adopted by players? What is the growth outlook of the global Commercial Robotics market?

The data of the market research report has been studied, compiled and corroborated by leading experts and established authors. The format followed in the report is in accordance with most international market research reports. However, if you have any specific requirements, you can get in touch with us, and we will modify the report accordingly.

Do Enquiry For Customized Report as per Your [emailprotected]https://www.marketresearchport.com/reports/2015-2025-global-commercial-robotics-market-research-report-by-product-type-applications-key-players-and-reg/55401

Table of Content:Chapter 1 Market Overview1.1 Market Definition And Segment1.1.1 Product Definition1.1.2 Product Type1.1.3 End-Use1.1.4 Marketing Channel1.2 Major Regions1.2.1 Europe Market Size And GrowthFigure Europe Commercial Robotics Market Size And Growth Rate, 2015e-2020f (Million Usd)Figure Europe Commercial Robotics Market Forecast And Growth Rate, 2020e-2025f (Million Usd)1.2.2 America Market Size And GrowthFigure America Commercial Robotics Market Size And Growth Rate, 2015e-2020f (Million Usd)Figure America Commercial Robotics Market Forecast And Growth Rate, 2020e-2025f (Million Usd)1.2.3 Asia Market Size And GrowthFigure Asia Commercial Robotics Market Size And Growth Rate, 2015e-2020f (Million Usd)Figure Asiacommercial Robotics Market Forecast And Growth Rate, 2020e-2025f (Million Usd)1.2.4 Oceania Market Size And GrowthFigure Oceania Commercial Robotics Market Size And Growth Rate, 2015e-2020f (Million Usd)Figure Oceania Commercial Robotics Market Forecast And Growth Rate, 2020e-2025f (Million Usd)1.2.5 Africa Market Size And GrowthFigure Africa Commercial Robotics Market Size And Growth Rate, 2015e-2020f (Million Usd)Figure Africa Commercial Robotics Market Forecast And Growth Rate, 2020e-2025f (Million Usd)

Chapter 2 Global Market Segmentation2.1 Global Production OverviewTable Global Commercial Robotics Production Volume (Volume), Ex-Factory Price, Revenue (Million Usd) And Gross Margin (%) List, 2015-20202.2 Global Consumption OverviewTable Global Commercial Robotics Consumption Volume (Volume), Terminal Price And Consumption Value (Million Usd) List, 2015-20202.3 Global Production By TypeTable Global Commercial Robotics Revenue By Type, 2015-2020 (Million Usd)Figure Global Commercial Robotics Revenue Share By Type In 2020 (Million Usd)Table Global Commercial Robotics Production Volume By Type, 2015-2020 (Volume)Figure Global Commercial Robotics Production Volume Share By Type In 2020 (Volume)2.4 Global Consumption By End-UseTable Global Commercial Robotics Consumption Value By End-Use, 2015-2020 (Million Usd)Figure Global Commercial Robotics Consumption Value Share By End-Use In 2020 (Million Usd)Table Global Commercial Robotics Consumption Volume By End-Use, 2015-2020 (Volume)Figure Global Commercial Robotics Consumption Volume Share By End-Use In 2020 (Volume)2.5 Global Consumption By RegionTable Global Commercial Robotics Consumption Value By Region, 2015-2020 (Million Usd)Table Global Commercial Robotics Consumption Volume By Region, 2015-2020 (Volume)

Chapter 3 Europe Market Segmentation3.1 Europe Production OverviewTable Europe Commercial Robotics Production Volume (Volume), Ex-Factory Price, Revenue (Million Usd) And Gross Margin (%) List, 2015-20203.2 Europe Consumption OverviewTable Europe Commercial Robotics Consumption Volume (Volume), Terminal Price And Consumption Value (Million Usd) List, 2015-20203.3 Europe Production By TypeTable Europe Commercial Robotics Revenue By Type, 2015-2020 (Million Usd)Figure Europe Commercial Robotics Revenue Share By Type In 2020 (Million Usd)Table Europe Commercial Robotics Production Volume By Type, 2015-2020 (Volume)Figure Europe Commercial Robotics Production Volume Share By Type In 2020 (Volume)3.4 Europe Consumption By End-UseTable Europe Commercial Robotics Consumption Value By End-Use, 2015-2020 (Million Usd)Figure Europe Commercial Robotics Consumption Value Share By End-Use In 2020 (Million Usd)Table Europe Commercial Robotics Consumption Volume By End-Use, 2015-2020 (Volume)Figure Europe Commercial Robotics Consumption Volume Share By End-Use In 2020 (Volume)3.5 Europe Consumption By RegionTable Europe Commercial Robotics Consumption Value By Region, 2015-2020 (Million Usd)Table Europe Commercial Robotics Consumption Volume By Region, 2015-2020 (Volume)

Chapter 4 America Market Segmentation4.1 America Production OverviewTable America Commercial Robotics Production Volume (Volume), Ex-Factory Price, Revenue (Million Usd) And Gross Margin (%) List, 2015-20204.2 America Consumption OverviewTable America Commercial Robotics Consumption Volume (Volume), Terminal Price And Consumption Value (Million Usd) List, 2015-20204.3 America Production By TypeTable America Commercial Robotics Revenue By Type, 2015-2020 (Million Usd)Figure America Commercial Robotics Revenue Share By Type In 2020 (Million Usd)Table America Commercial Robotics Production Volume By Type, 2015-2020 (Volume)Figure America Commercial Robotics Production Volume Share By Type In 2020 (Volume)4.4 America Consumption By End-UseTable America Commercial Robotics Consumption Value By End-Use, 2015-2020 (Million Usd)Figure America Commercial Robotics Consumption Value Share By End-Use In 2020 (Million Usd)Table America Commercial Robotics Consumption Volume By End-Use, 2015-2020 (Volume)Figure America Commercial Robotics Consumption Volume Share By End-Use In 2020 (Volume)4.5 America Consumption By RegionTable America Commercial Robotics Consumption Value By Region, 2015-2020 (Million Usd)Table America Commercial Robotics Consumption Volume By Region, 2015-2020 (Volume)

Chapter 5 Asia Market Segmentation5.1 Asia Production OverviewTable Asia Commercial Robotics Production Volume (Volume), Ex-Factory Price, Revenue (Million Usd) And Gross Margin (%) List, 2015-20205.2 Asia Consumption OverviewTable Asia Commercial Robotics Consumption Volume (Volume), Terminal Price And Consumption Value (Million Usd) List, 2015-20205.3 Asia Production By TypeTable Asia Commercial Robotics Revenue By Type, 2015-2020 (Million Usd)Figure Asia Commercial Robotics Revenue Share By Type In 2020 (Million Usd)Table Asia Commercial Robotics Production Volume By Type, 2015-2020 (Volume)Figure Asia Commercial Robotics Production Volume Share By Type In 2020 (Volume)5.4 Asia Consumption By End-UseTable Asia Commercial Robotics Consumption Value By End-Use, 2015-2020 (Million Usd)Figure Asia Commercial Robotics Consumption Value Share By End-Use In 2020 (Million Usd)Table Asia Commercial Robotics Consumption Volume By End-Use, 2015-2020 (Volume)Figure Asia Commercial Robotics Consumption Volume Share By End-Use In 2020 (Volume)5.5 Asia Consumption By RegionTable Asia Commercial Robotics Consumption Value By Region, 2015-2020 (Million Usd)Table Asia Commercial Robotics Consumption Volume By Region, 2015-2020 (Volume)

Chapter 6 Oceania Market Segmentation6.1 Oceania Production OverviewTable Oceania Commercial Robotics Production Volume (Volume), Ex-Factory Price, Revenue (Million Usd) And Gross Margin (%) List, 2015-20206.2 Oceania Consumption OverviewTable Oceania Commercial Robotics Consumption Volume (Volume), Terminal Price And Consumption Value (Million Usd) List, 2015-20206.3 Oceania Production By TypeTable Oceania Commercial Robotics Revenue By Type, 2015-2020 (Million Usd)Figure Oceania Commercial Robotics Revenue Share By Type In 2020 (Million Usd)Table Oceania Commercial Robotics Production Volume By Type, 2015-2020 (Volume)Figure Oceania Commercial Robotics Production Volume Share By Type In 2020 (Volume)6.4 Oceania Consumption By End-UseTable Oceania Commercial Robotics Consumption Value By End-Use, 2015-2020 (Million Usd)Figure Oceania Commercial Robotics Consumption Value Share By End-Use In 2020 (Million Usd)Table Oceania Commercial Robotics Consumption Volume By End-Use, 2015-2020 (Volume)Figure Oceania Commercial Robotics Consumption Volume Share By End-Use In 2020 (Volume)6.5 Oceania Consumption By RegionTable Oceania Commercial Robotics Consumption Value By Region, 2015-2020 (Million Usd)Table Oceania Commercial Robotics Consumption Volume By Region, 2015-2020 (Volume)

Chapter 7 Africa Market Segmentation7.1 Africa Production OverviewTable Africa Commercial Robotics Production Volume (Volume), Ex-Factory Price, Revenue (Million Usd) And Gross Margin (%) List, 2015-20207.2 Africa Consumption OverviewTable Africa Commercial Robotics Consumption Volume (Volume), Terminal Price And Consumption Value (Million Usd) List, 2015-20207.3 Africa Production By TypeTable Africa Commercial Robotics Revenue By Type, 2015-2020 (Million Usd)Figure Africa Commercial Robotics Revenue Share By Type In 2020 (Million Usd)Table Africa Commercial Robotics Production Volume By Type, 2015-2020 (Volume)Figure Africa Commercial Robotics Production Volume Share By Type In 2020 (Volume)7.4 Africa Consumption By End-UseTable Africa Commercial Robotics Consumption Value By End-Use, 2015-2020 (Million Usd)Figure Africa Commercial Robotics Consumption Value Share By End-Use In 2020 (Million Usd)Table Africa Commercial Robotics Consumption Volume By End-Use, 2015-2020 (Volume)Figure Africa Commercial Robotics Consumption Volume Share By End-Use In 2020 (Volume)7.5 Africa Consumption By RegionTable Africa Commercial Robotics Consumption Value By Region, 2015-2020 (Million Usd)Table Africa Commercial Robotics Consumption Volume By Region, 2015-2020 (Volume)

Chapter 8 Global Market Forecast8.1 Global Commercial Robotics Production ForecastFigure Global Commercial Robotics Revenue And Growth Rate Forecast 2020e-2025f (Million Usd)Figure Global Commercial Robotics Production Volume And Growth Rate Forecast 2020e-2025f (Volume)8.2 Global Commercial Robotics Forecast By TypeTable Global Commercial Robotics Revenue By Type, 2020e-2025f (Million Usd)Figure Global Commercial Robotics Revenue Share By Type In 2025 (Million Usd)Table Global Commercial Robotics Production Volume By Type, 2020e-2025f (Volume)Figure Global Commercial Robotics Production Volume Share By Type In 2025 (Volume)8.3 Global Commercial Robotics Forecast By End-Use (2020e-2025f)Table Global Commercial Robotics Consumption Value By End-Use, 2020e-2025f (Million Usd)Figure Global Commercial Robotics Consumption Value Share By End-Use In 2025 (Million Usd)Table Global Commercial Robotics Consumption Volume By End-Use, 2020e-2025f (Volume)8.4 Global Commercial Robotics Forecast By Region (2020e-2025f)Table Global Commercial Robotics Consumption Value By Region, 2020e-2025f (Million Usd)Figure Global Commercial Robotics Consumption Value Share By Region In 2025 (Million Usd)Table Global Commercial Robotics Consumption Volume By Region, 2020e-2025f (Volume)Figure Global Commercial Robotics Consumption Volume Share By Region In 2025 (Volume)

Chapter 9 Global Major Companies List9.1 Northrop Grumman Corporation9.1.1 Northrop Grumman Corporation ProfileTable Northrop Grumman Corporation Overview List9.1.2 Northrop Grumman Corporation Products & Services9.1.3 Northrop Grumman Corporation Company Dynamics & News9.1.4 Northrop Grumman Corporation Business Operation ConditionsTable Business Operation Of Northrop Grumman Corporation (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)9.2 Kuka Ag9.2.1 Kuka Ag ProfileTable Kuka Ag Overview List9.2.2 Kuka Ag Products & Services9.2.3 Kuka Ag Company Dynamics & News9.2.4 Kuka Ag Business Operation ConditionsTable Business Operation Of Kuka Ag (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)9.3 Irobot Corporation9.3.1 Irobot Corporation ProfileTable Irobot Corporation Overview List9.3.2 Irobot Corporation Products & Services9.3.3 Irobot Corporation Company Dynamics & News9.3.4 Irobot Corporation Business Operation ConditionsTable Business Operation Of Irobot Corporation (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)9.4 Yaskawa Electric Corporation9.4.1 Yaskawa Electric Corporation ProfileTable Yaskawa Electric Corporation Overview List9.4.2 Yaskawa Electric Corporation Products & Services9.4.3 Yaskawa Electric Corporation Company Dynamics & News9.4.4 Yaskawa Electric Corporation Business Operation ConditionsTable Business Operation Of Yaskawa Electric Corporation (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)9.5 Honda Motor Company Ltd.9.5.1 Honda Motor Company Ltd. ProfileTable Honda Motor Company Ltd. Overview List9.5.2 Honda Motor Company Ltd. Products & Services9.5.3 Honda Motor Company Ltd. Company Dynamics & News9.5.4 Honda Motor Company Ltd. Business Operation ConditionsTable Business Operation Of Honda Motor Company Ltd. (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)9.6 Omron Adept Technologies Inc.9.6.1 Omron Adept Technologies Inc. ProfileTable Omron Adept Technologies Inc. Overview List9.6.2 Omron Adept Technologies Inc. Products & Services9.6.3 Omron Adept Technologies Inc. Company Dynamics & News9.6.4 Omron Adept Technologies Inc. Business Operation ConditionsTable Business Operation Of Omron Adept Technologies Inc. (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)9.7 3d Robotics Inc.9.7.1 3d Robotics Inc. ProfileTable 3d Robotics Inc. Overview List9.7.2 3d Robotics Inc. Products & Services9.7.3 3d Robotics Inc. Company Dynamics & News9.7.4 3d Robotics Inc. Business Operation ConditionsTable Business Operation Of 3d Robotics Inc. (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)9.8 Accuray Inc.9.8.1 Accuray Inc. ProfileTable Accuray Inc. Overview List9.8.2 Accuray Inc. Products & Services9.8.3 Accuray Inc. Company Dynamics & News9.8.4 Accuray Inc. Business Operation ConditionsTable Business Operation Of Accuray Inc. (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)9.9 Alphabet Inc.9.9.1 Alphabet Inc. ProfileTable Alphabet Inc. Overview List9.9.2 Alphabet Inc. Products & Services9.9.3 Alphabet Inc. Company Dynamics & News9.9.4 Alphabet Inc. Business Operation ConditionsTable Business Operation Of Alphabet Inc. (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)9.10 Amazon Robotics Llc9.10.1 Amazon Robotics Llc ProfileTable Amazon Robotics Llc Overview List9.10.2 Amazon Robotics Llc Products & Services9.10.3 Amazon Robotics Llc Company Dynamics & News9.10.4 Amazon Robotics Llc Business Operation ConditionsTable Business Operation Of Amazon Robotics Llc (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)

Part 10 Market Competition10.1 Key Company Market ShareTable Global Commercial Robotics Sales Revenue 2015-2020e, By Companies, In Usd MillionTable Global Commercial Robotics Sales Revenue Share, 2015-2020e, By Companies, In UsdTable Global Commercial Robotics Sales Volume By Companies, 2015-2020e (Volume)Table Global Commercial Robotics Sales Volume Share By Companies, 2015-2020e (Volume)10.2 Regional Market ConcentrationFigure Europe Commercial Robotics Market Concentration Ratio In 2020eFigure America Commercial Robotics Market Concentration Ratio In 2020eFigure Asia Commercial Robotics Market Concentration Ratio In 2020eFigure Oceania Commercial Robotics Market Concentration Ratio In 2020eFigure Africa Commercial Robotics Market Concentration Ratio In 2020e

Part 11 Coronavirus Impact On Commercial Robotics Industry11.1 Impact On Industry Upstream11.2 Impact On Industry Downstream11.3 Impact On Industry Channels11.4 Impact On Industry Competition11.5 Impact On Industry Obtain Employment

Part 12 Commercial Robotics Industry Summary & Conclusion

About Us:Market Research Port is one of the best report resellers in the market bringing to you accurate and trustworthy market research reports by reputed publishers. Our trusted publishers have compiled their reports and findings after painstaking research and studies, set up against varied business parameters. Each report is detailed and then vetted for accuracy by industry experts. In each report, you will find deep analysis, risk analysis, market forecasts, emerging trends, different market segments, technological advancement and its impact, and a multitude of economic factors, giving you the most comprehensive market research report. You get many advantages with such comprehensive reports.

Contact Us:Market Research Port,Brighton Street, Providence,Rhode Island 02929, United StatesContact No: +1 401 433 7610Email: [emailprotected]Website: https://marketresearchport.com/

Follow this link:

Commercial Robotics Market 2020 Opportunities, Growth Analysis, Trends and Forecast by 2026 | Northrop Grumman Corporation, KUKA AG, iRobot...

‘There’s a real taboo’: Emma Gannon’s debut novel Olive explores the decision to be childfree – Belfast Telegraph

Posted on by

Ask any female novelist about the most annoying question they get asked in interviews, and many will admit that they're often asked about how much of the character is written from real life. It's a question that author Emma Gannon is having to field a lot right now.

It definitely does annoy me a little bit," she laughs. "Other female authors have prepared me in advance about how I'll get asked this, although it's up to me how much I want to reveal."

As it stands, Gannon has much in common with the protagonist of her lively and readable debut novel, Olive. In it, the British podcaster/journalist mulls over a pertinent question: what does a life without children look like for a modern woman in her thirties?

Naturally, Gannon's own stance on wanting children has emerged. As a journalist, Gannon has already written about how much she enjoys her child-free existence.

"I felt conflicted about it," she tells me, referring to her decision to disclose her own stance on wanting kids.

"Part of me wants to do the eye-roll, and there are people who think I've pretty much written a memoir. But on the other hand, I feel I'd be doing a disservice to the reader if I didn't talk about it. We do write about what we know, and I'm not going to pretend that this is something that has nothing to do with me."

Gannon's titular protagonist finds herself at a crossroads, trying to figure out many things. Flying high in her career as a journalist, a freshly single Olive is more than aware that her 'child-free by choice' status marks her out as a bit of an outlier.

As her friends gravitate towards marriage and motherhood (and all the struggles and challenges therein), Olive is forced to check back in with herself and re-evaluate her stance on not wanting children.

Gannon handles this with elan, putting on the page the various complexities, challenges and uncertainties of the child-free existence.

"There is a sense of being a little exposed, but when you write fiction you're in a bit of an invisibility cloak, and you can wander around saying all these interesting things through the mouths of your character," Gannon smiles. "Sometimes, they do come from my deepest, darkest thoughts - works of fiction are weirdly truthful."

Though Olive is the undisputed heroine of the book, her college pals Cecily, Bea and Isla are also forging their own territory as parents; something that afforded Gannon the chance to "play with ideas of what motherhood can be".

"I suppose that sort of symbolises how I feel," she says. "I'm 31. I don't think I want children. I don't want to set it in stone as it's too soon to make any kind of definitive statement about it, but it's been fun writing the alternative."

Engaged to be married next year, Gannon hears the 'you'll be next' refrain from well-meaning types more often than she'd like. "When I'm with my nephews, I get a lot of that," she smiles. "The other one I get is, 'you'll change your mind eventually'. My favourite though is, 'who will look after you when you're older?' The one I find quite offensive is, 'maybe you've not met the right person yet'. I've met the right person - that's not the issue. We're not yet at the point where someone will say that they don't want children and people will just go, 'oh right, that's cool'.

Unlike Gannon, Olive, at 33, is absolute in her decision that she wants to remain child-free. It's not easy to find characters like Olive in today's swathe of fiction, which is exactly why Gannon decided to write the book.

"I do think it's something we need to talk about more, about what 'child-free' means for a new generation," Gannon notes.

One motif that still somehow endures is that of a 'cold war' between child-free women and mothers, and it's an idea that Gannon wanted to tease out in Olive.

"It's a weird one, isn't it? I did hear someone say that once in a workplace, they sort of hinted that the child-free should be doing more of the work. I suppose I wanted to bust the myth that child-free people always have so much time. The truth is, there's a lot going on for a lot of us. And just because you don't have children, you can still nurture and love and give back.

"I think this is a book about how we are all more similar than we think, there is no real divide there - no binary," Gannon continues.

"Womanhood comes in many forms, and the 'us and them' is just problematic. Some people would love to have children, and can't. How lovely would it be if we could all just work together and just live and let live, in a beautiful harmony?

"Ultimately, at the heart of the book, I wanted to write about friends - people who have been in the same boat, gone through school and university together, and feel they have the same benchmarks to hit. Suddenly, in your thirties, you can feel distant from them, and threatened by their new life: 'will they stop seeing you if you have a child?' I think these are very typical fears that come to mind for women.

"It speaks to the insecurities women feel - are we making the right choice? You can often tell when you're being horrible to someone or a bit mean, it's often to do with fear, and being scared of someone making judgements on you. You start to worry about things like, 'is my friend ahead in her career?' There's a real taboo around those kinds of judgments among friends.

"So many people have said, 'Olive feels so true to me, as I've had these sort of fallouts with friends'," Gannon adds. "People say they don't get invited to mum things anymore if they don't have their own child. I'm glad the novel is painting that reality. Luckily, I don't have those struggles with my own friends - we respect each other's priorities and whenever I, say, have a book launch or something, my friends are there, showing up."

Teasing apart taboos and having tricky conversations has long been part of Gannon's professional lifeblood. And her innate curiosity has made her podcast, Ctrl Alt Delete, one of the most popular business podcasts in the UK.

"I think I always knew I wanted a job where I could get to be nosy and ask a lot of questions," Gannon says. "I love having the sort of conversations that make me uncomfortable. Curiosity often leads the way - I like that it helps you learn more."

With over six million downloads, Ctrl Alt Delete has seen Gannon interview everyone from Sharon Horgan and US actor Ellen Page to director Greta Gerwig and Gillian Anderson about their work lives. It was also the first podcast recorded inside Buckingham Palace.

"I genuinely love every single person I've interviewed but I often think back to the interview with (philosopher) Alain de Botton, because he just comes at things from a very different angle."

Her non-fiction debut, Ctrl Alt Delete, was released in 2016, and was swiftly followed by The Multi-Hyphen Method, "a new business book for the digital age".

In it, Gannon extols the virtues of a 'portfolio career', and exploring our own entrepreneurial spirit to create many strings for our own bows. Talking to people who run blogs or run online stores in their spare time, Gannon's book suggests working less and creating more and defining your own version of success.

"I don't necessarily agree that everyone should have a side hustle - it's another plate to spin for some people, but if you have a passion project, or an idea, and have whatever it takes to get started, ask yourself, will it improve your mental health? Will it help you meet new people? Are you happier being creative? "It's not even about making more money - it's about something that brings you joy."

Although released two years ago, The Multi-Hyphen Method has even more relevance in the current climate, where people in lockdown have been re-evaluating their work lives.

"It's a strange one, isn't it?" Gannon agrees.

"Two years ago I was talking about flexible working and new ways of working, and basically how a full-time job isn't a safety net anymore, and no one really wanted to hear it. No one really believed that flexible working could be the future. There was still a sense that people must still go to their desks and work from nine to five.

"It's been interesting, it's like we've been thrown into this social experiment (during the pandemic)," she adds. "Two years ago I had CEOs tell me they'd never allow employees to work from home, but now they're all working from home."

In The Multi-Hyphen Method, Gannon also writes of the benefits of self-promotion. "It's really hard for some people - either it comes naturally to them, or the thought paralyses them with fear," asserts Gannon.

"I tend to tell people that we're now living in a culture where self-promotion is pretty much part of the job. So much recruitment is done online, and there's a lot of competitiveness with the internet, and if you're not showing up for yourself on social media, it does have a knock-on effect. There's a way to self-promote that doesn't feel icky or boasty. Just use the way you'll tell your best friend what you're doing. It really is an extension of the job, and it will help you get more work."

With success in both the fiction and non-fiction realm, Gannon is now working, true to form, on a number of different side projects in addition to her podcast and day job.

"Maybe there's another novel (in my future), but I have another non-fiction book about self-sabotage out in September, too," she reveals. "I wrote Olive in secret, almost like an experiment. I don't necessarily want to leave non-fiction behind. I love that world far too much."

Olive by Emma Gannon, published by HarperCollins, 14.99

Read more:

'There's a real taboo': Emma Gannon's debut novel Olive explores the decision to be childfree - Belfast Telegraph

Victimless or Consensual Crime – Criminal Classification

Posted on by

Victimless crime, also called consensual crime, refers to crime that doesn't directly harm the person or property of another.2 min read

Victimless Crime

Victimless crime, also called consensual crime, refers to crime that doesn't directly harm the person or property of another. Victimless crimes are typically not included in the common law, and are considered crimes mala prohibita. Some activities that are considered victimless crimes in a majority of jurisdictions are:

A lively debate continues as to whether victimless crimes really are "victimless," and some crimes legally regarded as victimless, such as prostitution, stand in the forefront of debate over whether anyone is harmed or not, physically, morally, or otherwise.

Arguments Against Prosecution of Victimless Crime

A common argument for ending prosecution of consensual crimes is that prosecuting these activities causes more harm to society that simply decriminalizing them. A few popular examples cited for this argument are the War on Drugs and its ramifications, overcrowded jails and prisons, and the high cost of prosecuting and punishing people for crimes, which it is argued, cause less damage to society than the "solution." In the United States, estimates tower at $40 billion per year just for prosecuting consensual crimes. This cost is in addition to the costs of incarcerating people who, it is argued, don't belong behind bars to begin with.

Arguments For Prosecution of Victimless Crime

There are several arguments for maintaining the prosecution of victimless crime. There are arguments regarding costs, but the main thrust of maintaining prosecution tends to be rooted in arguing that society as a whole is enhanced by locking up victimless criminal offenders.

One argument runs that, while the cost of additional law enforcement and the prosecution of consensual crime is high, the financial costs that would result from decriminalizing activities such as drug use, unbuckled seat-belts, drunk driving, and possession of some kinds of firearms would be unacceptably high.

Second, it is argued that the cost to the core values of society would be very grave for decriminalizing activities such as prostitution, bigamy and some forms of gambling. It is argued that decriminalization would drastically diminish overall quality of life, inflicting real harm on the fabric of society.

See also:

Read this article:

Victimless or Consensual Crime - Criminal Classification

The Definition, Types, and Examples of Victimless Crimes …

Posted on by

What we have here is some information on victimless crimes, wherein we put forth the definition of this concept and also discuss its types with some examples, so as to make it easier for you to understand the same.

When Russia legalized homosexuality for a brief period following the 1917 Bolshevik Revolution, it was based on the idea that if there was no victim, there was no crime.

That the United States has the highest prison population rate in the world for more than a decade now, is a well-known fact. What most people dont know, is that over 80 percent of these inmates are incarcerated for victimless crimes, i.e., crimes that defy societys prohibition of certain activities. So is there actually something called victimless crime or crime where there is no victim? While the term may not boast of popular usage, the statistical data, which states that over 80 percent of people in the prison are convicted for such crimes, does speak volumes in itself.

As the name suggests, victimless crimes are those crimes wherein there is no apparent victim, as such a person or property is not harmed physically. An apt definition will be illegal behavior which does not violate or threaten anyones rights. The person may either act alone (e.g. drug abuse or gambling), or two or more people can be involved in a consensual act (e.g. prostitution).

Example: Lets take the example of prostitution for instance. In the United States, offering sexual favors in lieu of money is considered a criminal act, wherein both parties can be arrested for violating public decency laws. If, however, both of them have given their consent to the act, then neither of them can be considered a victim.

It is worth noting that such crimes usually happen in confined spaces, and therefore, other people are unlikely to take of note of them. As nobody is watching and nobody is victimizedthose involved do not consider themselves victimsthere is no complainant in such cases. Instead, the police have to take action on their own. As a result of this, it is a lot more difficult to detect and prosecute victimless crimes compared to crimes wherein there are victims.

As these crimes have the consent of those people involved, they are sometimes known as consensual crimes. In a true sense though, consensual crimes are crimes involving more than one participant, all of whom give their consent.

Depending on the area of jurisdiction, the lengthy list of victimless crimes includes drug abuse, prostitution, gambling, public drunkenness, homosexuality, vagrancy, obscenity, riding a bike without a helmet, or driving a motor vehicle without a seat belt, as well as more serious crimes like abortion and suicide. In the United States, for instance, illicit drug abuse, prostitution, and gambling are considered victimless crimes.

In a broad sense, these crimes can be grouped into different types. For example, there are moral crimes, wherein the particular illegal act has something to do with the morality or norms set by the society. Homosexuality between consenting adults, for instance, is considered a victimless crime on the grounds that it violates common decency laws. Other examples of such crimes include sodomy, public drunkenness, and even vagrancy. Then there are crimes against the state, such as tax frauds, not carrying an ID, carrying a gun without license, etc., which also fall in this category.

Adultery was considered a victimless crime at one point of time, but has since been removed from the list.

Many people call for outlawing laws which prohibit victimless acts. They argue that it hampers the individuals freedom, as he is at the receiving end despite his consent. Additionally, some people are of the opinion that incarceration of people convicted for such crimes puts immense pressure on the already crowded prison system. As opposed to this, those in favor of victimless crimes being punished argue that the representatives of the majority have the right to prohibit and punish anyone who indulges in any act that offends the majority of the population, even if there is no direct victim.

See the original post here:

The Definition, Types, and Examples of Victimless Crimes ...